Timothy M. Schmidt

1.1k total citations
29 papers, 579 citations indexed

About

Timothy M. Schmidt is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Timothy M. Schmidt has authored 29 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 21 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Timothy M. Schmidt's work include Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (6 papers). Timothy M. Schmidt is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (6 papers). Timothy M. Schmidt collaborates with scholars based in United States, Nepal and Greece. Timothy M. Schmidt's co-authors include Rafaël Fonseca, Saad Z. Usmani, Natalie S. Callander, Luciano J. Costa, Susan Bal, Bhagirathbhai Dholaria, Kelly Godby, Eva Medvedova, Smith Giri and Robert F. Cornell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Timothy M. Schmidt

27 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy M. Schmidt United States	9	476	397	268	68	63	29	579
Véronique Dorvaux France	10	280 0.6×	295 0.7×	190 0.7×	83 1.2×	35 0.6×	18	423
Carolina Martínez‐Laperche Spain	15	354 0.7×	105 0.3×	126 0.5×	92 1.4×	65 1.0×	61	587
Kevin Liu New Zealand	10	551 1.2×	425 1.1×	383 1.4×	63 0.9×	16 0.3×	16	729
Mohit Narang United States	12	435 0.9×	298 0.8×	272 1.0×	74 1.1×	32 0.5×	64	526
Morgan Mace United States	4	244 0.5×	158 0.4×	84 0.3×	76 1.1×	23 0.4×	8	351
Mourad Tiab France	10	347 0.7×	270 0.7×	175 0.7×	41 0.6×	49 0.8×	42	407
M. Fopp Switzerland	15	318 0.7×	228 0.6×	253 0.9×	56 0.8×	127 2.0×	29	837
D. Treille France	8	372 0.8×	265 0.7×	386 1.4×	102 1.5×	76 1.2×	13	687
Karen Pekle United States	12	484 1.0×	254 0.6×	238 0.9×	58 0.9×	23 0.4×	39	656
Tatjana Spasokoukotskaja Sweden	11	79 0.2×	299 0.8×	154 0.6×	212 3.1×	92 1.5×	17	516

Countries citing papers authored by Timothy M. Schmidt

Since Specialization

Citations

This map shows the geographic impact of Timothy M. Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy M. Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy M. Schmidt more than expected).

Fields of papers citing papers by Timothy M. Schmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy M. Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy M. Schmidt. The network helps show where Timothy M. Schmidt may publish in the future.

Co-authorship network of co-authors of Timothy M. Schmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy M. Schmidt. A scholar is included among the top collaborators of Timothy M. Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy M. Schmidt. Timothy M. Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Timothy M., Rafaël Fonseca, Rajshekhar Chakraborty, et al.. (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer Journal. 14(1). 20–20. 10 indexed citations

Schmidt, Timothy M., Zhubin Gahvari, & Natalie S. Callander. (2024). SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24(10). 653–664. 2 indexed citations

Mishra, A., et al.. (2023). PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 30(2). 191–202. 9 indexed citations

Gahvari, Zhubin, Matthew Brunner, Timothy M. Schmidt, & Natalie S. Callander. (2023). Update on the current and future use of CAR‐T to treat multiple myeloma. European Journal Of Haematology. 112(4). 493–503. 3 indexed citations

Silbermann, Rebecca, Timothy M. Schmidt, Susan Bal, et al.. (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation. SHILAP Revista de lepidopterología. 4(3). 775–778. 2 indexed citations

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901. 71 indexed citations

Costa, Luciano J., Eva Medvedova, Bhagirathbhai Dholaria, et al.. (2023). S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL. HemaSphere. 7(S3). e1332195–e1332195. 3 indexed citations

Bal, Susan, Binod Dhakal, Rebecca Silbermann, et al.. (2022). Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology. 97(9). 1170–1177. 5 indexed citations

Chhabra, Saurabh, Rebecca Silbermann, Bhagirathbhai Dholaria, et al.. (2021). Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S70–S70.

10.

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations

11.

Schmidt, Timothy M., Rafaël Fonseca, & Saad Z. Usmani. (2021). Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer Journal. 11(4). 83–83. 83 indexed citations

12.

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 21. S33–S33. 1 indexed citations

13.

Costa, Luciano J., Saurabh Chhabra, Natalie S. Callander, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. Blood. 138(Supplement 1). 481–481. 6 indexed citations

14.

Bal, Susan, Saurabh Chhabra, Natalie S. Callander, et al.. (2021). Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood. 138(Supplement 1). 483–483. 2 indexed citations

15.

Schmidt, Timothy M. & Natalie S. Callander. (2020). Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 18(12). 1720–1729. 3 indexed citations

16.

Schmidt, Timothy M., Benjamin G. Barwick, Nisha S. Joseph, et al.. (2019). Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal. 9(12). 94–94. 108 indexed citations

17.

Schmidt, Timothy M., Nisha S. Joseph, Benjamin G. Barwick, et al.. (2019). Gain of Chromosome 1q is Associated with Early Progression in Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Dexamethasone. Clinical Lymphoma Myeloma & Leukemia. 19(10). e76–e77. 20 indexed citations

18.

Schmidt, Timothy M., et al.. (2018). Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. Anticancer Research. 38(7). 4027–4034. 8 indexed citations

19.

Schmidt, Timothy M., Nisha S. Joseph, Leonard T. Heffner, et al.. (2018). Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. Blood. 132(Supplement 1). 3241–3241. 1 indexed citations

20.

Liegler, Teri, Mohamed Abdel‐Mohsen, L. Gordon Bentley, et al.. (2014). HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. The Journal of Infectious Diseases. 210(8). 1217–1227. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact